ASCO Gastrointestinal Cancers Symposium

Dr. Filippo Pietrantonio explores the manageable safety profile of amivantamab combined with chemotherapy for metastatic colorectal cancer patients.

Dr. Filippo Pietrantonio explores how amivantamab may transform surgical options for patients with advanced colorectal cancer, enhancing treatment outcomes.

New data from the OrigAMI-1 study highlights promising efficacy and safety of amivantamab with chemotherapy for metastatic colorectal cancer patients.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

Filippo Pietrantonio discusses overcoming resistance in metastatic colorectal cancer with innovative trials for amivantamab, enhancing treatment efficacy.

New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.

New trial data highlight zanidatamab's potential to enhance survival in HER2-positive gastroesophageal adenocarcinoma, challenging existing treatment standards.

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

Susumu Hijioka, MD, discusses the key takeaways from the phase 3 STARTER-NET trial evaluating the combination of everolimus with lanreotide when used for the first-line treatment of patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS G12D pancreatic ductal adenocarcinoma based on preliminary findings.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in patients with KRAS G12D pancreatic ductal adenocarcinoma treated with zoldonrasib.

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.

Fruquintinib plus TAS-102 showed clinical activity in heavily pretreated metastatic colorectal cancer.

Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical antitumor activity in patients with refractory metastatic colorectal cancer.

Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.

Encorafenib, cetuximab, and mFOLFOX6 improved overall response rate over mFOLFOX6 alone in BRAF V600E-mutant mCRC, per BREAKWATER data.

SCRT plus cadonilimab and chemotherapy showed positive pCRs and acceptable safety in pMMR/MSS locally advanced rectal cancer.

Nivolumab plus ipilimumab significantly improved PFS over nivolumab alone in dMMR/MSI-H metastatic CRC in the CheckMate 8HW trial.

Balstilimab plus botensilimab improved ORR over botensilimab alone in MSS mCRC without liver metastases, per phase 2 data.

Single-cycle neoadjuvant pembrolizumab proved safe and effective in dMMR colon cancer, per RESET-C trial findings.